NCT06568614View on ClinicalTrials.gov

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 12, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2028

Conditions
Advanced or Metastatic MTAP-deleted Solid Tumors
Interventions
DRUG

BG-89894

Administered orally

Trial Locations (3)

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

510120

RECRUITING

Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou

050011

RECRUITING

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Sponsors

Lead Sponsor

BeOne Medicines
All Listed Sponsors
lead

BeOne Medicines

INDUSTRY

NCT06568614 - An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter